Olstein Capital Management L.P. Sells 9,657 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Olstein Capital Management L.P. decreased its holdings in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 8.9% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 99,343 shares of the company's stock after selling 9,657 shares during the period. Olstein Capital Management L.P. owned approximately 0.08% of Henry Schein worth $6,804,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in HSIC. Palestra Capital Management LLC bought a new stake in Henry Schein in the 4th quarter worth $182,988,000. Lyrical Asset Management LP bought a new stake in shares of Henry Schein in the fourth quarter worth about $126,655,000. Norges Bank bought a new stake in shares of Henry Schein in the fourth quarter worth about $103,301,000. Steadfast Capital Management LP increased its holdings in Henry Schein by 254.2% during the 4th quarter. Steadfast Capital Management LP now owns 1,637,808 shares of the company's stock valued at $113,336,000 after purchasing an additional 1,175,408 shares during the period. Finally, Hudson Bay Capital Management LP raised its position in Henry Schein by 102.1% during the 4th quarter. Hudson Bay Capital Management LP now owns 1,465,007 shares of the company's stock valued at $101,378,000 after purchasing an additional 740,007 shares during the last quarter. Institutional investors own 96.62% of the company's stock.

Henry Schein Stock Down 0.1%

Shares of Henry Schein stock traded down $0.06 during midday trading on Thursday, hitting $71.08. The company had a trading volume of 1,189,185 shares, compared to its average volume of 1,683,417. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.49. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The company has a 50 day moving average of $68.01 and a 200 day moving average of $71.56. The stock has a market capitalization of $8.65 billion, a P/E ratio of 29.25, a P/E/G ratio of 2.13 and a beta of 0.86.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.11 by $0.04. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. Henry Schein's revenue for the quarter was down .1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.10 EPS. On average, equities analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Henry Schein news, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares of the company's stock, valued at approximately $1,762,147.20. The trade was a 9.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the transaction, the chief executive officer now directly owns 62,688 shares in the company, valued at $4,460,251.20. The trade was a 6.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.08% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on HSIC. Piper Sandler reduced their target price on Henry Schein from $83.00 to $77.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 30th. Barrington Research decreased their price objective on shares of Henry Schein from $90.00 to $86.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. UBS Group dropped their target price on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research report on Wednesday, February 26th. Wells Fargo & Company reduced their price target on shares of Henry Schein from $80.00 to $75.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Finally, Wall Street Zen downgraded shares of Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $79.30.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.